937236-73-2

Basic information

• Product Name: ethyl 2-(2-chloropyridin-4-yl)acetate
• Synonyms: ethyl 2-(2-chloropyridin-4-yl)acetate
• CAS NO: 937236-73-2
• Molecular Weight: 199.637
• Mol File: 937236-73-2.mol

Chemical Properties

• CAS DataBase Reference: ethyl 2-(2-chloropyridin-4-yl)acetate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 2-(2-chloropyridin-4-yl)acetate(937236-73-2)
• EPA Substance Registry System: ethyl 2-(2-chloropyridin-4-yl)acetate(937236-73-2)

Safety Data

• Hazardous Substances Data: 937236-73-2(Hazardous Substances Data)

Upstream product

• 101990-73-2 2-chloro-pyridin-4-ylmethyl chloride 
• 64-17-5 ethanol 
• 201230-82-2 carbon monoxide 
• 105-58-8 Diethyl carbonate 
• 3678-62-4 2-chloro-4-picoline 

Downstream Products

• 887580-55-4 2-(2-chloropyridin-4-yl)acetic acid 
• 1220627-15-5 tert-butyl (4-(2-hydroxyethyl)pyridin-2-yl)carbamate 
• 1220627-18-8 tert-butyl (4-(2-((4-(3-(3-(tert-butyl)-1-(p-tolyl)-1H-pyrazol-5-yl)ureido)naphthalen-1-yl)oxy)ethyl)pyridin-2-yl)carbamate 
• 1206247-86-0 2-(2-chloropyridin-4-yl)ethan-1-ol 
• 1256337-00-4 3-(2-((2-tert-butoxycarbonylamino-pyridin-4-ylacetyl)-amino)-2-(2,9,9-trimethyl-3,5-dioxa-4-bora-tricyclo[6.1.1.0(2,6)]dec-4-yl)-ethyl)-2-methoxy-benzoic acid tert-butyl ester 
• 1256336-19-2 (2R)-3-{2-[(2-amino-pyridin-4-ylacetyl)-amino]-2-borono-ethyl}-2-hydroxy-benzoic acid 
• 887580-70-3 2-[2-(tert-butoxycarbonylamino)pyridin-4-yl]acetic acid 
• 945989-03-7 4-(5-bromo-2-(4-phenethylthiazol-2-ylamino)pyridin-4-yl)-3-oxobutanoate 
• 945989-01-5 ethyl 2-(5-bromo-2-(4-phenethylthiazol-2-ylamino)pyridin-4-yl)acetate 
• 945989-02-6 2-(5-bromo-2-(4-phenethylthiazol-2-ylamino)pyridin-4-yl)acetic acid 
• 945988-99-8 ethyl 2-(2-(3-benzoylthioureido)-5-bromopyridin-4-yl)acetate 
• 1229649-68-6 1-(4-(1-(2-aminopyridin-4-yl)propan-2-yloxy)naphthalen-1-yl)-3-(3-tert-butyl-1-p-tolyl-1H-pyrazol-5-yl)urea 
• 1229649-43-7 N-(4-(1-(4-(3-(3-tert-butyl-1-p-tolyl-1H-pyrazol-5-yl)ureido)naphthalen-1-yloxy)propan-2-yl)pyridin-2-yl)-2-methoxyacetamide 
• 1229649-74-4 tert-butyl 4-(1-(4-(3-(3-tert-butyl-1-p-tolyl-1H-pyrazol-5-yl)ureido)naphthalen-1-yloxy)propan-2-yl)pyridin-2-ylcarbamate 

Relevant articles and documents

METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS

The subject matter described herein is directed to ferroportin inhibitor compounds of Formula (I) and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds, and methods of administering the compounds for prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, particularly iron overload states, such as thalassemia, sickle cell disease and hemochromatosis, and also kidney injuries.

Inhibitors of Hemopoietic Cell Kinase (P59-HCK) and Their Use in the Treatment of Influenza Infection

The present invention relates inter alia to the treatment or prevention of influenza virus infection (including subtypes influenza A virus, influenza B virus, avian strain H5N1, A/H1N1, H3N2 and/or pandemic influenza) using compounds which inhibit the act

LABELLED COUMARIN DERIVATIVES

The present invention relates to compounds having selective binding for MAO-B as compared with MAO-A. The invention also provides radioactive versions of these compounds, and precursor compounds for the synthesis of these radioactive compounds. The radioactive compounds of the invention can find use for in vivo imaging applications.

QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR INHIBITORS

Compounds of formula (Ι') that are Fibroblast Growth Factor Inhibitors (FGFR) and are therefore useful for the treatment of diseases treatable by inhibition of FGFR are disclosed. Also disclosed are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

INHIBITORS OF HEMOPOIETIC CELL KINASE (P59-HCK) AND THEIR USE IN THE TREATMENT OF INFLUENZA INFECTION

The present invention relates inter alia to the treatment or prevention of influenza virus infection (including subtypes influenza A virus, influenza B virus, avian strain H5N1, A/H1N1, H3N2 and/or pandemic influenza) using compounds which inhibit the activity of p59-HCK and to a method of screening for a candidate drug substance intended to prevent or treat influenza virus infection in a subject, said method comprising identifying a test substance capable of inhibiting p59-HCK activity.

BETA-LACTAMASE INHIBITORS

Disclosed herein are α-aminoboronic acids and their derivatives which act as inhibitors of beta-lactamases. Also disclosed herein are pharmaceutical compositions comprising α-aminoboronic acids and methods of use thereof.

GLUCOKINASE ACTIVATORS

Provided are compounds of formula I that are useful in the treatment and/or prevention of diseases mediated by deficient levels of glucokinase activity, such as diabetes mellitus. Also provided are methods of treating or preventing diseases and disorders characterized by underactivity of glucokinase or which can be treated by activating glucokinase. (Formula I) wherein R2, L, Z, Y, G and R1 are as defined in the claims.

SPIRO IMIDAZOLE DERIVATIVES AS PPAR MODULATORS

The invention provides compounds (Ia), (Ib) and (Ic), pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of the Peroxisome Proliferator-Activated

NOVEL INHIBITORS OF PROTEIN KINASE

The present invention relates to novel compounds for inhibition of angiogenesis receptor tyrosine kinases, in particular, VEGF receptor 2 kinase ("KDR") activity, and preparations for preparation of them, and the use of them, and pharmaceutical compositions containing them at a therapeutically effective amount. The compounds according to the present invention are useful for the treatment and prevention of diseases resulting from the undesired KDR activity, for example, angiogenesis-related diseases such as cancers, psoriasis, rheumatoid arthritis, diabetic retinopathy, etc.